Biogen’s monoclonal antibody felzartamab was approved in China for the treatment of multiple myeloma. Felzartamab will be available in China for second-line multiple myeloma patients alongside lenalidomide and the corticosteroid dexamethasone. Yesterday's approval comes just ...